1. Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist.
- Author
-
Wu, Hui, Wang, Gao-Rui, Wang, Xin-Ting, Bai, Yu-Yan, Yuan, Jin-Feng, Yang, Liu, Huang, Fei, Shi, Hai-Lian, and Wu, Xiao-Jun
- Subjects
LIPID metabolism ,HYPERTENSION ,OBESITY ,BIOCHEMISTRY ,STATISTICS ,INTRAVENOUS therapy ,CELL culture ,TRITERPENES ,ANIMAL experimentation ,LIVER ,PHENOMENOLOGICAL biology ,WESTERN immunoblotting ,ONE-way analysis of variance ,PEROXISOME proliferator-activated receptors ,METABOLIC disorders ,TREATMENT effectiveness ,HYPERLIPIDEMIA ,GENE expression ,COMPARATIVE studies ,T-test (Statistics) ,MESSENGER RNA ,DESCRIPTIVE statistics ,RESEARCH funding ,MOLECULAR structure ,COMPUTER-assisted molecular modeling ,POLYMERASE chain reaction ,DATA analysis ,MICE ,INSULIN resistance ,ANTIOBESITY agents ,LIGANDS (Biochemistry) ,CHEMICAL inhibitors - Abstract
Metabolic disorder is highly related to obesity, insulin resistance, hypertension, and hyperlipidemia. The present study found that astragaloside IV (ASI) attenuated metabolic disorder related symptoms and modulated hepatic lipid metabolism associated gene mRNA expression in db/db mice. ASI inhibited rosiglitazone-induced adipocyte differentiation of 3T3-L1 cells, and lipid accumulation in palmitic acid (PA)-induced HepG2 cells with down-regulated mRNA expression of lipogenesis-related genes. In addition, it was predicted to bind to the ligand binding domain (LBD) of PPARγ and inhibit its transactivity. Collectively, our study suggested that ASI improves lipid metabolism in obese mice probably through suppressing PPARγ activity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF